22CEMIT is a non-profit, general incorporated association aimed at delivering the best treatment to cancer patients by conducting a business to exchange and share the knowledge of all healthcare professionals involved in cancer treatment.
- Dr.Yoshino, chairman of 22CEMIT, has started the world's largest investigator-initiated trial.
- Interview featuring Dr.Yoshino, chairman of 22CEMIT, has been published in Microsoft's medical website.
- Interview featuring Dr. Yoshino, chairman of 22CEMIT, has been published in BEST DOCTORS IN JAPAN.
- The technology developed by Natera Inc "To judge the possibility of cancer recurrence at 90% accuracy" has been invterviewd by TV Asahi Corporation.
- Cancer Genomic Medical Online Course is now available at Docomo gacco